Gene eXpression Technologies (GXT) Program
GXT Program Provides Diverse Expression Technologies
Since purchasing the Pichia pastoris Yeast Protein Expression System in 1993, RCT has acquired an array of the world's most widely used gene expression systems, tools and genes for a convenient and affordable licensing program.
RCT launched the Gene eXpression Technologies (GXT) program in 2000 to help relieve some of the complex royalty burdens faced by biopharmaceutical and gene therapy companies. GXT licenses are flexible and nonexclusive, with manageable fees and royalties based on fields of use.
The GXT portfolio includes the Pichia Yeast Protein Expression System, the InsectSelect™ Insect Cell Expression System, the bovine growth hormone polyadenylation (bgh-polyA) signal sequence, an antibody scaffold, and several promoters and enhancers.
Today, the Pichia system is licensed to more than 120 companies in the biotechnology, pharmaceutical, animal health and food industries. An improvement to the system, a set of GlycoSwitch Pichia strains, enables the glycoforms of secreted proteins to be tightly controlled. The choices include glycoforms very similar to human glycosylation but lacking a fucose residue. These new strains produce proteins that may have increased applications for human therapies.
The bgh-polyA signal sequence acquired from Case Western Reserve University in 1997 is now licensed to more than 100 biotechnology and pharmaceutical companies. This versatile DNA sequence provides mRNA stability and a high level of protein expression in mammalian cells.
GXT Program Seeks New Technologies
We invite companies and universities to submit technologies for possible inclusion in the GXT portfolio. We seek new or existing patented technologies that can generate royalties on production of proteins or therapeutic uses. Our interests include:
- Promoters: Cell specific; regulated; high production potential
- Vectors: Regulated; high production potential
- Protein Expression Systems: Novel "complete" systems w/ vectors and hosts
- Genetic Control Elements: Enhancers; terminators
- Nucleic Acid Delivery Systems
- Novel Protein Scaffolds
- Display Technologies
All technologies must have commercial potential beyond uses as "research tools."
For additional information
David Bramhill, Ph.D., Director
Phone: (520) 748-4443
Fax: (520) 748-0025
Tell Us About Your Technology
If you have a technology that meets our criteria and needs further development and commercialization, we would like to hear from you. Please contact us to begin a confidential review of your opportunity.